• / Free eNewsletters & Magazine
  • / My Account
Home>Personalized Medicine Markets 2016-2026 - Scientific and Commercial Aspects Report 2017 - Research and Markets

Personalized Medicine Markets 2016-2026 - Scientific and Commercial Aspects Report 2017 - Research and Markets

Personalized Medicine Markets 2016-2026 - Scientific and Commercial Aspects Report 2017 - Research and Markets

09/20/2017

Personalized Medicine Markets 2016-2026 - Scientific and Commercial Aspects Report 2017 - Research and Markets

The "Personalized Medicine - Scientific and Commercial Aspects" report from Jain PharmaBiotech has been added to Research and Markets' offering.

This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping.

Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines.

Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2016-2026.

Profiles of 323 companies involved in developing technologies for personalized medicines, along with 585 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 83 tables and 39 figures.

Key Topics Covered:

©2017 Morningstar Advisor. All right reserved.